TY - JOUR
T1 - A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development
T2 - IUPHAR Review 29
AU - Alexander, Steve P.H.
AU - Armstrong, Jane F.
AU - Davenport, Anthony P.
AU - Davies, Jamie A.
AU - Faccenda, Elena
AU - Harding, Simon D.
AU - Levi-Schaffer, Francesca
AU - Maguire, Janet J.
AU - Pawson, Adam J.
AU - Southan, Christopher
AU - Spedding, Michael
N1 - Publisher Copyright:
© 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society
PY - 2020/11/1
Y1 - 2020/11/1
N2 - In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
AB - In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
UR - http://www.scopus.com/inward/record.url?scp=85085497792&partnerID=8YFLogxK
U2 - 10.1111/bph.15094
DO - 10.1111/bph.15094
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 32358833
AN - SCOPUS:85085497792
SN - 0007-1188
VL - 177
SP - 4942
EP - 4966
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 21
ER -
